Physician profile
Jitendra Bhatt
NPI 1497805352
$542.51
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $145.17 | 2019 | |
| Novo Nordisk INC | $62.15 | 2019 | |
| Amarin Pharma, INC. | $51.56 | 2019 | |
| Abbvie INC. | $51.18 | 2019 | |
| Sanofi-Aventis U.S. LLC | $41.13 | 2019 | |
| Genentech USA, INC. | $32.47 | 2019 | |
| Glaxosmithkline, LLC. | $32.05 | 2019 | |
| Janssen Pharmaceuticals, INC | $30.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.49 | 2019 | |
| Merck Sharp & Dohme LLC | $23.08 | 2019 | |
| Pfizer INC. | $20.69 | 2019 | |
| Astellas Pharma US INC | $15.81 | 2019 | |
| Allergan, INC. | $11.73 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jitendra Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.